Burrowing through the heterogeneity: Review of mouse models of PTCL-NOS

Frontiers in Oncology

Volumn 7, Issue SEP, 2016, Pages

  Cutucache, Christine E ^a   Herek, Tyler A ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Genetically engineered; Mouse models; Neoplasms; PTCL NOS; T cell lymphoma

Indexed keywords

T LYMPHOCYTE RECEPTOR;

CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL HETEROGENEITY; CELL PROLIFERATION; CYTOGENETICS; DISEASE SEVERITY; GENE MUTATION; GENE OVEREXPRESSION; IMMUNE RESPONSE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; SHORT SURVEY; TUMOR MICROENVIRONMENT;

EID: 84991826692     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00206     Document Type: Short Survey

References (41)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 3(7):730-7. doi: 10.1038/nm0797-730
2. Dick JE. Stem cell concepts renew cancer research. Blood (2008) 112(13):4793-807. doi:10.1182/blood-2008-08-077941
3. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther (2009) 17(2):219-30. doi:10.1038/mt.2008.254
4. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent uon activity of BRG1, the ATPase of the SWI. SNF chromatin remodeling complex. Cancer Res (2009) 69(20):8094-101. doi:10.1158/0008-5472.CAN-09-0733
5. Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J (2015) 36(3):273-9. doi:10.15537/smj.2015.3.9622
6. Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med (2015) 4(9):1033-43. doi:10.5966/sctm.2015-0048
7. Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams, and therapies. J Clin Pathol (2008) 61(11):1160-7. doi:10.1136/jcp.2008.055335
8. Kuppers R, Klein U, Hansmann M-L, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med (1999) 341:1520-9. doi:10.1056/NEJM199911113412007
9. Rudiger T, Geissinger E, Muller-Hermelink HK. 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol Oncol (2006) 24(4):175-80. doi:10.1002/hon.786
10. Savage KJ. Peripheral T-cell lymphomas. Blood Rev (2007) 21(4):201-16. doi:10.1016/j.blre.2007.03.001
11. Wang X, Werneck MBF, Wilson BG, Kim H-J, Kluk MJ, Thom CS, et al. TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest (2011) 121(10):3834-45. doi:10.1172/JCI37210
12. Toya T, Nannya Y, Hangaishi A, Shiseki M, Shimoyama T, Sakamaki H, et al. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study. Leuk Lymphoma (2016) 54(4):961-4. doi:10.3109/10428194.2015.1083097
13. Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med (2010) 207(5):1031-44. doi:10.1084/jem.20092042
14. Pattengale PK, Taylor CR. Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol (1983) 113(2):237-65.
15. Warner K, Crispatzu G, Al-Ghaili N, Weit N, Florou V, You MJ, et al. Models for mature T-cell lymphomas-a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts. Crit Rev Oncol Hematol (2013) 88(3):680-95. doi:10.1016/j.critrevonc.2013.07.014
16. Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev (2013) 32:63-76. doi:10.1007/s10555-012-9405-5
17. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer (2001) 31(3):248-54. doi:10.1002/gcc.1141
18. Bug S, Durig J, Oyen F, Klein-Hitpass L, Martin-Subero JI, Harder L, et al. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-ell pyolymhocytic leukeas with TCL1A-TCRAD juxtaposition. Cancer Genet Cytogenet (2009) 192(1):44-7. doi:10.1016/j.cancergencyto.2009.03.001
19. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell (2002) 2(5):415-25. doi:10.1016/S1535-6108(02)00185-X
20. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 26(17):2795-9. doi:10.1200/JCO.2008.17.7436
21. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 4(2):199-207. doi:10.1016/S1097-2765(00)80367-6
22. Ishiguro A, Spirin K, Shiohara M, Tobler A, Norton JD, Rigolet M, et al. Expression of Id2 and Id3 mRNA in human lymphocytes. Leuk Res (1995) 19(12):989-96. doi:10.1016/0145-2126(95)00084-4
23. Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G. Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. Mol Immunol (1999) 36(8):491-503. doi:10.1016/S0161-5890(99)00071-1
24. Cotta CV, Leventaki V, Atsaves V, Vidaki A, Schlette E, Jones D, et al. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. Cancer (2008) 112(3):552-61. doi:10.1002/cncr.23196
25. Nagel S, Venturini L, Marquez VE, Meyer C, Kaufmann M, Scherr M, et al. Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer (2010) 151(9):151. doi:10.1186/1476-4598-9-151
26. Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia (2008) 22(6):1139-43. doi:10.1038/leu.2008.77
27. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, et al. Critical role for the tyrosine kinase Syk in signaling through the high affinity IgE receptor of mast cells. Oncogene (1996) 13:2595-605.
28. Teramoto H, Salem P, Robbins KC, Bustelo XR, Gutkind JS. Tyrosine phosphorylation of the vac proto-oncogene product links FceRI to the Rac1-JNK pathway. J Biol Chem (1997) 272:10751-5. doi:10.1074/jbc.272.16.10751
29. Cornal RJ, Cheng AM, Pawson T, Goodnow CC. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci U S A (2000) 97:1713-8. doi:10.1073/pnas.97.4.1713
30. Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Herchenbach D, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res (2010) 70(15):6193-204. doi:10.1158/0008-5472.CAN-08-3719
31. Chan AC, van Oers NS, Tran A, Turka L, Law CL, Ryan JC, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol (1994) 152:4758-66.
32. Orchansky PL, Matsuuchi L, Ericsson PO, Teh HS. Differential regulation of p72syk expression in naïve and proliferating CD4-8+T cells. Mol Immunol (1996) 33:835-46. doi:10.1016/0161-5890(96)84609-8
33. Chu DH, van Oers NS, Malissen M, Harris J, Elder M, Weiss A. Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression. J Immunol (1999) 163:2610-20.
34. Beachy SH, Onozawa M, Chung YJ, Slape C, Bilke S, Francis P, et al. Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma. Blood (2012) 120(5):1048-59. doi:10.1182/blood-2012-01-401760
35. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell (1991) 67(5):879-88. doi:10.1016/0092-8674(91)90361-2
36. Dutta S, Krause A, Vosberg S, Herold T, Ksienzyk B, Quintanilla-Martinez L, et al. The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. Leukemia (2016) 30(5):1166.76. doi:10.1038/leu.2015.349
37. Munoz NM, Katz LH, Shin J-H, Jin Gi Y, Menon VK, Gagea M, et al. Generation of a mouse model of T-cell lymphoma based on chronic LPS challenge and TGF-β signaling disruption. Genes Cancer (2014) 5(9-10):348-52. doi:10.18632/genesandcancer.32
38. Canela A, Martin-Caballero J, Flores JM, Blasco MA. Constitutive expression of tert in thymocytes leads to increased incidence and dissemination of T-cell lymphoma in Lck-Tert mice. Mol Cell Biol (2004) 24(10):4275-93. doi:10.1128/MCB.24.10.4275-4293.2004
39. Ortega M, Bhatnager H, Lin AP, Wang L, Aster JC, Sill H, et al. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B-and T-cell malignancies. Leukemia (2015) 29(4):968-76. doi:10.1038/leu.2014.302
40. Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia (2015) 30(5):1062-70. doi:10.1038/leu.2015.357
41. Friend LD, Shah DD, Deppong C, Lin J, Bricker TL, Juehne TI, et al. A dose-dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted knockin mutant. J Exp Med (2006) 203(9):2121-33. doi:10.1084/jem.20052230